Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Wright

Showing results (111-120 of 158) with videos related to

Pageof 16
Sort By:
Journal of the American Heart Association|November 18, 2016
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS TrialBarbara E Stähli, Catherine Gebhard, Valérie Duchatelle, et al.
Chest|February 26, 2011
Patients with obstructive sleep apnea exhibit impaired endothelial function after myocardial infarctionFatima H Sert Kuniyoshi, Prachi Singh, Apoor S Gami, et al.
The New England Journal of Medicine|March 21, 2020
Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J Raal, David Kallend, Kausik K Ray, et al.
The New England Journal of Medicine|March 19, 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolKausik K Ray, R Scott Wright, David Kallend, et al.
JAMA Cardiology|July 27, 2018
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Christie M Ballantyne, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery diseaseJoseph Murphy, R Scott Wright, Ihor Gussak, et al.
European Heart Journal|November 4, 2022
Inclisiran and cardiovascular events: a patient-level analysis of phase III trialsKausik K Ray, Frederick J Raal, David G Kallend, et al.
The New England Journal of Medicine|March 18, 2017
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL CholesterolKausik K Ray, Ulf Landmesser, Lawrence A Leiter, et al.
Mayo Clinic Proceedings|August 19, 2014
A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gapsFrancisco Lopez-Jimenez, Vinaya Simha, Randal J Thomas, et al.
Journal of the American College of Cardiology|March 5, 2021
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or AtherosclerosisR Scott Wright, Kausik K Ray, Frederick J Raal, et al.
Pageof 16

Showing results (111-120 of 158) with videos related to

Sort By:
Pageof 16
Journal of the American Heart Association|November 18, 2016
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS TrialBarbara E Stähli, Catherine Gebhard, Valérie Duchatelle, et al.
Chest|February 26, 2011
Patients with obstructive sleep apnea exhibit impaired endothelial function after myocardial infarctionFatima H Sert Kuniyoshi, Prachi Singh, Apoor S Gami, et al.
The New England Journal of Medicine|March 21, 2020
Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaFrederick J Raal, David Kallend, Kausik K Ray, et al.
The New England Journal of Medicine|March 19, 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolKausik K Ray, R Scott Wright, David Kallend, et al.
JAMA Cardiology|July 27, 2018
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Christie M Ballantyne, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery diseaseJoseph Murphy, R Scott Wright, Ihor Gussak, et al.
European Heart Journal|November 4, 2022
Inclisiran and cardiovascular events: a patient-level analysis of phase III trialsKausik K Ray, Frederick J Raal, David G Kallend, et al.
The New England Journal of Medicine|March 18, 2017
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL CholesterolKausik K Ray, Ulf Landmesser, Lawrence A Leiter, et al.
Mayo Clinic Proceedings|August 19, 2014
A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gapsFrancisco Lopez-Jimenez, Vinaya Simha, Randal J Thomas, et al.
Journal of the American College of Cardiology|March 5, 2021
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or AtherosclerosisR Scott Wright, Kausik K Ray, Frederick J Raal, et al.
Pageof 16